Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media

American Journal of the Medical Sciences

Volumn 339, Issue 1, 2010, Pages 25-30

  Alexopoulos, Elias ^a   Spargias, Konstantinos ^a   Kyrzopoulos, Stamatis ^a   Manginas, Athanassios ^a   Pavlides, Gregory ^a   Voudris, Vassilis ^a   Lerakis, Stamatios ^b   McLean, Dalton S ^b   Cokkinos, Dennis V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Contrast induced nephropathy; Coronary procedure; Iso osmolar contrast media; Low osmolar contrast media; Renal dysfunction

Indexed keywords

ASCORBIC ACID; CONTRAST MEDIUM; IOBITRIDOL; IODIXANOL; IOMEPROL; IOPENTOL; IOXAGLIC ACID; PLACEBO;

ACUTE DISEASE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DEMOGRAPHY; FEMALE; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; OSMOLARITY; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL;

EID: 75449083008     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181c06e70     Document Type: Article

References (49)

1. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int 2006;100:S11-5.
2. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379-386
3. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375
4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494
5. Gruberg I, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 hours of intervention in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-1548
6. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002;39:1113-1119
7. Solomon R. The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high-risk patients. Kidney Int 2005;68:2256-2263
8. Solomon R, Biguori C, Bettmann M. Selection of contrast media. Kidney Int 2006;100:S39-45.
9. Persson PB, Hansell P, Liss P. Pathophysiology of contrast mediuminduced nephropathy. Kidney Int 2005;68:14-22.
10. Persson PB, Patzak A. Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydraton. Nephrol Dial Transplant 2005;20(suppl 1):2-5.
11. Sharma SK, Kini A. Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mildmoderate chronic renal insufficiency: pooled analysis of the randomized trials. Catheter Cardiovasc Interv 2005;65:386-393
12. Schräder R. Contrast material-induced renal failure: an overview. J Interv Cardiol 2005;18:417-423
13. Solomon R, DuMouchel W. Contrast media and nephropathy: findings from systemic analysis and Food and Drug Administration reports of adverse effects. Invest Radiol 2006;41:651-660
14. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188:171-178
15. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499
16. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995;47:254-261
17. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-2207
18. Hans S, Hans BA, Dhillon R, et al. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 1998;64:432-436
19. Miner SE, Dzavick V, Nguyen-Ho P, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during longterm follow-up. Am Heart J 2004;148:690-695
20. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-2117
21. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003; 58:336-341
22. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). A randomized comparison of 3 preventive strategies. Circulation 2007; 115:1211-1217
23. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004;110:2837-2842
24. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999;83:260-263
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
26. Hardiek K, Katholi RE, Ramkumar V, et al. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol 2001;280:F61-70.
27. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int 2006;100:S8 -10.
28. Tervahartiala P, Kivisaari L, Kivisaari R, et al. Structural changes in the renal proximal tubular cells induced by iodinated contrast media. Nephron 1997;76:96-102.
29. Beaufils H, Idee JM, Berthommier C, et al. Iobitridol, a new nonionic low-osmolality contrast agent, and iohexol. Impact on renal histology in the rat. Invest Radiol 1995;30:33-39
30. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-2291
31. Oldemeyer JB, Biddle WP, Wurdeman RL, et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 2003;146:E23.
32. Goldenberg I, Shechter M, Matezky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. Eur Heart J 2004;25: 212-217
33. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-358
34. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002;223:772-779
35. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally impaired Patients (CARE) Study. A randomized double-blind trial of contrast induced nephropathy in patients with chronic kidney disease. Circulation 2007;115:3189-3196
36. Mehran R, Nikolsky E, Kirtane AJ, et al. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients. The ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study. JACC Cardiovasc Interv 2009;2:415-421
37. Rudnick MR, Davidson C, Laskey W, et al; VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008;156:776-782
38. Briguori C, Colombo A, Airoldi F, et al. N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2004;44:762-765 (Pubitemid 39099569)
39. Morikawa S, Sone T, Tsuboi H, et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 2009;53:1040-1046
40. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998;31:674-680
41. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-1680
42. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:1038-1046
43. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008;52:599-604.
44. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. JAMA 2003;289:553-558
45. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-1388
46. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184
47. Gomes VO, Poli de Figueredo CE, Caramori P, et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 2005;91:774-778
48. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40: 298-303.
49. Briguori C, Colombo A, Airoldi F, et al. Nephrotoxicity of lowosmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005;68:2250-2255